Simergent

Simergent develops innovative medical technology, specifically focusing on automated peritoneal dialysis systems designed to enhance patient experience and improve treatment outcomes for home dialysis. Founded in 2014 in Oklahoma City, US, Simergent specializes in automated peritoneal dialysis solutions. The company was co-founded by Rick Pendergraft and Steve Lindo, who has experience in medical technology. Simergent raised a total of USD 2.

840 mn through a Seed round led by i2E Inc. in April 2019. Simergent's primary product offering is the Archimedes automated peritoneal dialysis system, designed to enhance the home dialysis experience for patients. This device addresses significant challenges in home dialysis, such as high rates of peritonitis and mobility limitations.

The Archimedes features patented technology to reduce peritonitis risks and simplify training for new users, ultimately allowing patients to engage more fully in their daily lives. Simergent's revenue structure is primarily based on sales of its Archimedes system, which is currently not available for sale nor FDA-approved. The company plans to adopt a direct-to-consumer sales model for the system, although specific pricing plans have not been disclosed. Simergent aims to leverage the recent Seed funding of USD 2.

835 mn raised in April 2019 to further develop and refine the Archimedes system. The company is focused on completing the product design and pursuing FDA approval, with plans to enter the home dialysis market. Specific geographic expansions are still under consideration as they prepare for commercial availability.